The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Standard of care treatment approaches in MCL and the role of chemotherapy-free regimens
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses standard of care treatment approaches in mantle cell lymphoma (MCL) and further comments on the potential role of chemotherapy-free regimens. Prof. Vitolo first highlights treatment approaches for younger and elderly patients, and then goes on to discuss the efficacy of combining rituximab with ibrutinib and venetoclax. To conclude, Prof. Vitolo comments on the need to improve treatment options for patients with high-risk disease, highlighting the promise of using CAR-T cell therapy in earlier lines of treatment, and clinical trials in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
